Liraglutide Trial to Assess Sudomotor Function, Inflammation, and Oxidative Stress in Type 2 Diabetes

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. Beyond glycemic control, T2D often leads to microvascular complications, including diabetic neuropathy, which can manifest as impaired sudomotor function (sweating abnormalities). Chronic low-grade inflammation and increased oxidative stress are also hallmarks of T2D pathogenesis and contribute to its complications. Current treatments primarily focus on glucose lowering, but often fall short in addressing the broader spectrum of T2D-related complications, especially those affecting the autonomic nervous system and systemic inflammation. GLP-1 receptor agonists like Liraglutide have shown benefits beyond glycemic control, including cardiovascular protection and weight loss, prompting investigation into their potential effects on these less-explored T2D complications.